Yano Chizuko, Saeki Hidehisa, Komine Mayumi, Kagami Shinji, Tsunemi Yuichiro, Ohtsuki Mamitaro, Nakagawa Hidemi
Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan.
Department of Dermatology, Nippon Medical School, Tokyo, Japan.
Ann Dermatol. 2015 Apr;27(2):152-6. doi: 10.5021/ad.2015.27.2.152. Epub 2015 Mar 24.
CC chemokine ligand 17 (CCL17) and CCL22 are the functional ligands for CCR4. We previously reported that inhibitors of nuclear factor-kappa B and p38 mitogen-activated protein kinase (p38 MAPK), but not of extracellular signal-related kinase (ERK), inhibited tumor necrosis factor (TNF)-α- and interferon (IFN)-γ-induced production of CCL17 by the human keratinocyte cell line, HaCaT. Further, an inhibitor of epidermal growth factor receptor (EGFR) enhanced the CCL17 production by these keratinocytes.
To identify the mechanism underlying CCL22 production by HaCaT cells.
We investigated the signal transduction pathways by which TNF-α and IFN-γ stimulate HaCaT cells to produce CCL22 by adding various inhibitors.
TNF-α- and IFN-γ-induced CCL22 production was inhibited by PD98059, PD153035, Bay 11-7085, SB202190, c-Jun N-terminal kinase (JNK) inhibitor II, and Janus kinase (JAK) inhibitor 1.
Our results indicate that CCL22 production in HaCaT cells is dependent on ERK, EGFR, p38 MAPK, JNK, and JAK and is mediated by different signal pathways from those regulating CCL17 production. Altogether, our previous and present results suggest that EGFR activation represses CCL17 but enhances CCL22 production by these cells.
CC趋化因子配体17(CCL17)和CCL22是CC趋化因子受体4(CCR4)的功能性配体。我们之前报道过,核因子-κB和p38丝裂原活化蛋白激酶(p38 MAPK)的抑制剂可抑制肿瘤坏死因子(TNF)-α和干扰素(IFN)-γ诱导人角质形成细胞系HaCaT产生CCL17,但细胞外信号调节激酶(ERK)的抑制剂则无此作用。此外,表皮生长因子受体(EGFR)的抑制剂可增强这些角质形成细胞的CCL17产生。
明确HaCaT细胞产生CCL22的潜在机制。
我们通过添加各种抑制剂,研究了TNF-α和IFN-γ刺激HaCaT细胞产生CCL22的信号转导途径。
PD98059、PD153035、Bay 11-7085、SB202190、c-Jun氨基末端激酶(JNK)抑制剂II和Janus激酶(JAK)抑制剂1可抑制TNF-α和IFN-γ诱导的CCL22产生。
我们的结果表明,HaCaT细胞中CCL22的产生依赖于ERK、EGFR、p38 MAPK、JNK和JAK,且由与调节CCL17产生不同的信号途径介导。总之,我们之前和现在的结果表明,EGFR激活可抑制这些细胞的CCL17产生,但增强CCL22产生。